Loading...

Hikma Pharmaceuticals PLC

HIK.LLSE
Healthcare
Drug Manufacturers - Specialty & Generic
£1939.00
£-25.00(-1.27%)

Hikma Pharmaceuticals PLC (HIK.L) Stock Competitors & Peer Comparison

See (HIK.L) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
HIK.L£1,939.00-1.27%4.3B16.16£1.20+3.19%
HLN.L£365.40+1.64%32.8B21.49£0.17+1.48%
HCM.L£264.00-3.47%2.3B-66.00-£0.04N/A
INDV.L£1,238.00+1.56%1.5B-309.50-£0.04N/A
0IRF.IL£6.94-1.50%1.2B-11.96-£0.58N/A
AGY.L£8.00+0.00%381.3M-8.00-£0.01N/A
APH.L£64.70+0.00%349.7M-32.35-£0.02N/A
ANCR.L£268.00-1.47%184.9M33.50£0.08+1.87%
BXP.L£39.00+0.00%174M4.33£0.09+8.59%
BMK.L£22.60+6.10%167.8M-3.77-£0.06N/A
Showing 1 to 10 of 24 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

HIK.L vs HLN.L Comparison August 2025

HIK.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HIK.L stands at 4.3B. In comparison, HLN.L has a market cap of 32.8B. Regarding current trading prices, HIK.L is priced at £1,939.00, while HLN.L trades at £365.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HIK.L currently has a P/E ratio of 16.16, whereas HLN.L's P/E ratio is 21.49. In terms of profitability, HIK.L's ROE is +0.16%, compared to HLN.L's ROE of +0.09%. Regarding short-term risk, HIK.L is less volatile compared to HLN.L. This indicates potentially lower risk in terms of short-term price fluctuations for HIK.L.Check HLN.L's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;